Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strides Pharma ScienceNSE:STAR +2.25%66 EV-to-EBIT is 13.23 as of Jul. 28, 2026, which is 6% above its 10-year median of 12.50. GuruFocus rates NSE:STAR with a GF Score™ of 66/100 and a GF Value™ of ₹762.24 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 691 Drug Manufacturers companies, Strides Pharma Science ranks better than 57.02% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Strides Pharma Science's Enterprise Value for the quarter that ended in Mar. 2026 was ₹102,388 Mil.
Strides Pharma Science's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,472 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's EV-to-EBIT falls into.
Strides Pharma Science's current Enterprise Value is ₹112,089 Mil.
Strides Pharma Science's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,472 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strides Pharma Science (NSE:STAR) has a EV-to-EBIT of 13.23 as of Jul. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Strides Pharma Science and its competitors. This is near median its historical median of 12.50. According to the industry distribution chart, Strides Pharma Science ranks #297 out of 691 companies in the Drug Manufacturers industry, placing it in the top 43%.
Is Strides Pharma Science's EV-to-EBIT too high?
Strides Pharma Science's current EV-to-EBIT of 13.23 is near median its 10-year median of 12.50. The Drug Manufacturers industry median EV-to-EBIT is 15.42. Strides Pharma Science's value of 13.23 is 14.2% below this industry median. Based on the distribution chart, Strides Pharma Science ranks #297 out of 691 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Strides Pharma Science has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #297 out of 691 companies for EV-to-EBIT. This puts Strides Pharma Science in the upper half of its industry. The industry median EV-to-EBIT is 15.42. Strides Pharma Science's value of 13.23 is 14.2% below this benchmark. While the company's 10-year median is 12.50 vs. the industry median of 15.42, Strides Pharma Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.42, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strides Pharma Science's current EV-to-EBIT of 13.23 is 14.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Strides Pharma Science and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current EV-to-EBIT is 13.23, which is near median its own 10-year median of 12.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹762.24, compared to a current price of ₹1,043.00 — trading 36.8% above its estimated fair value. The current EV-to-EBIT is 13.23, which is near median its 10-year median of 12.50 and 14.2% below the Drug Manufacturers industry median of 15.42. Strides Pharma Science's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current EV-to-EBIT is 13.23 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,043.00 is trading 36.8% above its estimated GF Value™ of ₹762.24.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
EV-to-EBIT: 13.23 (near median its 10-year median of 12.50)
GF Value™: ₹762.24 vs. price of ₹1,043.00 (36.8% above fair value)
Industry Position: 14.2% below the Drug Manufacturers median (#297 of 691)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
66GF Score
Get the complete analysis for NSE:STAR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
